Multispecialty medical groups and integrated delivery systems expect fee-for-service payments to decline 24% in the next 2 years, according to results of a survey from the American Medical Group Association.
Multispecialty medical groups and integrated delivery systems expect fee-for-service payments to decline 24% in the next 2 years, according to results of a survey from the American Medical Group Association (AMGA).
The federal government is pushing more toward a value-based payment system with CMS’ announced timeline to tie 90% of Medicare payments to value by 2018 and the Medicare Access and CHIP Reauthorization Act. The AMGA survey sought to determine how healthcare financing is changing, current impediments to accepting risk, and the tools necessary for providers to take on risk.
“Our members understand the importance of transitioning to a value-based payment system, in fact many are already moving in that direction,” Chester A. Speed, JD, LLLM, vice president of public policy at AMGA, said in a statement. “This transition will be challenging and medical groups need policymakers and commercial insurers to partner with them to offer the tools they need to be successful in a new risk environment.”
From 2015 to 2017, respondents said they expect revenue from Medicare Advantage payments to increase 20%, from accountable care organization products to increase 36%, and from Medicaid managed care payments to increase 20%. At the same time, risk-based products in the commercial setting are expected to increase significantly.
However, currently, 22% of respondents said that no payer in their market is offering risk-based payment arrangements. In addition to the limited offering of risk products, respondents identified other impediments. Among commercial insurers there is a lack of access to full administrative claims data and a lack of transparency when it comes to cost and quality data. In the federal setting, there are operational difficulties in the ACO programs, ineffective attribution, and a lack of a standardized data submission and feedback process.
Overall, AMGA found that 58% of respondents say they need at least 3 years before they can accept downside risk.
“If policymakers want to successfully transform the current volume-based payment system to one based on value, they need to understand these impediments to risk-taking and offer the tools providers need to make this transition successful,” the authors of the report concluded. “If these issues are overlooked, the opportunity to reform the system for both the benefit of patients and programmatic efficiency may be lost.”
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More